Galectin Therapeutics Announces Positive Preclinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension

NORCROSS, Ga., June 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, reports that GR-MD-02, its development-stage galectin-3 (gal-3) inhibitor, has shown a positive effect on vascular remodeling in an animal model of pulmonary arterial hypertension (PAH). The results were presented at the American Thoracic Society (ATS) 2016 International Conference by investigators from the Vascular Biology Center and the Department of Pharmacology and Toxicology at Augusta University (formerly known as Georgia Regents University) (see poster presentation ).

PAH results in a progressive narrowing of the pulmonary arteries, which leads to increased vascular resistance and the elevation of pulmonary blood pressure and, ultimately, right ventricular heart failure. It is believed that the primary cause of the permanently elevated pulmonary vascular resistance that occurs in PAH is due to physical obstruction from vascular remodeling. There are a number of vasodilator drugs that are indicated for the treatment of PAH, but additional therapies are desirable to address the structural narrowing of pulmonary arteries.

The results of this study demonstrated that rat models of PAH have significantly increased right ventricular systolic pressure, right ventricular hypertrophy and pulmonary arterial smooth muscle proliferation and fibrosis, as well as increased right ventricular wall thickness and lower pulmonary blood flow. Further, in rats and humans with PAH, robust induction of gal-3 expression was observed in the smooth muscle layer. Treatment with the gal-3 inhibitors GR-MD-02 and GM-CT-01 resulted in marked improvement in the functional heart characteristics and the vascular remodeling (smooth muscle proliferation and fibrosis) associated with PAH. A more complete description of the findings can be found in a companion CEO Perspective blog post in addition to the poster presentation.

“The alterations in cardiopulmonary function and vascular proliferation, as well as in fibrosis were significantly attenuated by in vivo treatment with specific gal-3 inhibitors,” said David Fulton, Ph.D., Director of the Vascular Biology Center at Augusta University. “These findings indicate that gal-3 signaling contributes to the compromised pulmonary vascular function and prominent pulmonary arterial remodeling that occurs in PAH, which suggests that inhibition of gal-3 is a strategic and viable target for treatment of PAH and other related pulmonary vascular diseases.”

“We are intrigued by the results of this study, which suggest another important indication for therapy with our gal-3 inhibitors,” said Peter G. Traber, M.D., chief executive officer and chief medical officer of Galectin Therapeutics and one of the study’s authors. “The severity of PAH is such that over half of patients die of the disease within seven years of initial diagnosis. A new therapeutic approach that addresses vascular remodeling would be a welcome addition to the vasoactive drugs currently on the market.”

About Galectin Therapeutics Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis, psoriasis and cancer. Additional information is available at:   www.galectintherapeutics.com .   

Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that its lead compounds will be successful in treating fibrosis and cancer and that those compounds may be effective in the treatment of pulmonary arterial hypertension.  Regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials.  For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.

Contacts Jack Callicutt, Chief Financial Officer (678) 620-3186 ir@galectintherapeutics.com

LHA Kim Golodetz (212) 838-3777 kgolodetz@lhai.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 117

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 156

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 161

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 94

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

NewRiver REIT Announces Scrip Dividend Reference Price

Updated Category News Views 335

NewRiver REIT's Scrip Dividend Reference Price Announcement NewRiver REIT plc has made a significant announcement regarding the reference price for its scrip dividend option, which is tied to its interim dividend. This dividend pertains to the six-month period ending on September 30, 2024. Understanding the Scrip Dividend Option The reference price has been set at 73.41...

Continue Reading
Upcoming Shareholders' Meeting Announcement for Siguldas CMAS

Updated Category News Views 200

Important Shareholders' Meeting Information The Management Board of Joint Stock Company ‘Siguldas ciltslietu un m?ksl?g?s aps?klošanas stacija’ is excited to announce an important shareholders' meeting for the company. This meeting is a key opportunity for all shareholders to engage in discussions concerning the company's future. Meeting Details Scheduled for April...

Continue Reading
Empowering Women in Finance: Insights from Cboe Leaders

Updated Category News Views 168

Empowering Women in Finance In a recent dialogue, Cathy Clay, Executive Vice President and Global Head of Derivatives at Cboe, along with Meghan Dugan, Senior Vice President overseeing U.S. Options, and Alexandra Szakats, Vice President and Head of The Options Institute, shared their journeys and advice regarding their roles as leaders in the options industry. These women...

Continue Reading
Bird Dog Whiskey Debuts Premium Kentucky Straight Bourbon

Updated Category News Views 220

Bird Dog Whiskey Unveils Select Reserve Kentucky Straight Bourbon Bird Dog Whiskey has exciting news for bourbon enthusiasts. The brand has launched a highly anticipated addition to its lineup: the Select Reserve Kentucky Straight Bourbon Whiskey. This new offering is set to capture the hearts of loyal fans. A Smooth and Rich Bourbon Experience At 86 proof, Bird Dog...

Continue Reading
Vera Therapeutics Announced Key Stock Option Grants for New Hires

Updated Category News Views 160

Introduction to Vera Therapeutics' Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has proudly announced a significant step in its commitment to fostering talent by granting inducement awards to new employees. On a recent date, the Compensation Committee approved these awards, which included stock options and restricted stock units (RSUs) to reward and attract...

Continue Reading